Alert: Medical Psilocybin Drug Moves Closer to Market Post-Phase 3 Data

Compass Pathways has successfully completed its 26-week Phase 3 clinical trial data for COMP360 psilocybin, meeting its primary endpoint for treatment-resistant depression. This significant development, aiming for a potential H1 2027 launch, suggests a strengthening pathway for medical psilocybin. While not immediate, this progress could foreshadow future regulatory shifts and open new avenues or challenges for businesses in the psychedelics space.

Compass Pathways has successfully completed its 26-week Phase 3 clinical trial data for COMP360 psilocybin for treatment-resistant depression (TRD). The data, from Part B of the COMP006 trial, assessed doses of 1 mg, 10 mg, or 25 mg of psilocybin. The primary endpoint was met, with a -3.8 point difference on the MADRS at week 6 between the 25 and 1 mg groups. Today's report covers topline results from weeks 9-26, including an option for retreatment. This clinical advancement positions Compass Pathways for a potential H1 2027 launch, signaling a major step toward the medical availability of psilocybin.

Sentinel Insight